AzTrials
AzTrials

Alveolar Bone GraftingNCT02444052

Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation

A study testing Zimmer Puros Cancellous Allograft and Nobel Biocare Creos Cancellous Allograft in people with Alveolar Bone Grafting and Allograft, run by University of Florida at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate clinically, histologically and radiographically the healing of extraction sockets with Zimmer's Puros® allograft compared to creos™ (creo™ Nobel Biocare,), a low-cost allograft material, 90 days following exodontia. Read more about this study

Who is it for?
Ages 21 to 75 yearsHealthy volunteers can take part
What is being tested?
Zimmer Puros Cancellous Allograft and Nobel Biocare Creos Cancellous Allograft
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteUnited States
Study dates
Oct 2015to 1 Oct 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Systemically healthy subjects with two non-adjacent molar or premolar teeth located in the same jaw that require extraction and socket augmentation for implant site development (treatment sites may be located in either the mandibular or maxillary jaw)
  • Residual extraction sockets must have <70% bone loss in all dimensions (3 or 4-walled bony defects)
  • Nonsmokers (individuals who quit smoking at least 6 months prior to the study will be allowed to participate)
  • Subjects willing and able to comply with all study-related procedures including maintenance of good oral hygiene and compliance with re-evaluation appointments
  • Subjects who read, understand and are willing to sign an informed consent statement.

Who cannot join

  • Inadequate zone of keratinized gingiva (KG) or alveolar mucosa to obtain primary wound closure of the surgical site
  • Presence of acute infections at the time of tooth extraction
  • Clinically significant or unstable (as defined by the investigators) systemic diseases affecting bone or soft tissue growth; or other renal, hepatic, cardiac, endocrine, hematologic, autoimmune or acute infectious diseases that makes interpretation of the data more difficult
  • History of head \& neck radiation therapy
  • Subjects taking steroids, tetracycline or tetracycline analogs, bone therapeutic levels of fluorides, biphosphonates, medications affecting bone turnover, antibiotics for >7 days or any investigational drug
  • Patients who are or become pregnant during the length of the study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Florida College of Dentistry-Periodontics

    Gainesville, Florida, 32610

Other trials in United States

About this study

Official title: Clinical and Histological Evaluation of Zimmer Puros® Allograft vs. Creos™ (Low-cost) Allograft for Alveolar Ridge Preservation Following Exodontia

The purpose of this study is to evaluate clinically, histologically and radiographically the healing of extraction sockets with Zimmer's Puros® allograft compared to creos™ (creo™ Nobel Biocare,), a low-cost allograft material, 90 days following exodontia.

Read the detailed description

Twenty-four consecutive subjects requiring extraction of two non-adjacent molars or premolars located in the same jaw will be selected from the patient pool of the Center for Advanced Periodontology at the University of Florida, College of Dentistry.

Preoperative Procedures: At the initial screening, the goals of the study, potential risks and possible benefits will be explained and each subject will be asked to sign a written consent statement permitting extraction of the involved teeth and the placement of Puros® allograft and creos™ allograft for ridge preservation. After which a complete medical and dental history will be obtained, a pregnancy test will be performed, and establishment of inclusion and exclusion criteria will be determined. If meeting all study criteria, examination periapical radiographs will be taken and each subject will receive oral hygiene instructions, prophylaxis, and full-arch alginate impressions. The study models will also be used to fabricate occlusal templates to permit reproducible clinical measurements of the alveolar ridge dimensions of the residual tooth socket.

Surgical Protocol \& Treatment Assessment: To help minimize technical variances in the surgical treatment protocol, the primary investigator will perform baseline and 12-week re-entry surgeries. Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated; the selected teeth will be extracted atraumatically, followed by debridement of the sockets, and collection of all clinical measurements.The following clinical measurements will be made at the baseline and re-entry surgeries using standard University of North Carolina (UNC) manual probes (Hu-Friedy, Chicago, IL):

  1. Facial/buccal thickness (baseline, only)
  2. Distance from the occlusal template to the facial, lingual and crestal bone
  3. Socket depth (or template to crest distance at the 90-day re-entry surgery)
  4. Osseous dehiscence location and dimension
  5. Bone density (on re-entry)

The surgeon will then preserve each site with either Puros® allograft creos™ allograft. Puros® allograft will be placed into half of the extraction sockets to the level of the osseous crest. A bovine pericardium membrane (CopiOs ®Pericardium) will be then placed to cover the bone graft material. Primary closure will be achieved in all cases. The site will be sutured with 4.0 PTFE sutures. The other extraction sites will receive the same treatment but with creos™ allograft. Participants will be prescribed a 10 day regimen of Ibuprofen (2.4g/day) and antibiotics (amoxicillin (1.5g/day) or clindamycin (0.6g/day)) unless other allergies are present. Subjects will be instructed to change their diet to semi-liquid for 48 hours, followed by soft foods for the first 2-weeks. Subjects will also be instructed to begin rinsing with warm water, as needed, and to resume their normal oral hygiene routine the day after surgery in all areas except the surgical site.

At 2-week post-surgery, the extraction sites will be inspected and gently cleaned with saline-soaked gauze, health histories will be reviewed, oral hygiene instructions will be repeated, photographs will be taken; and a plaque score will be recorded. Cone beam CT images will be performed 2 weeks and 12 weeks post-operative. All imaging will be done using the Kodak limited view CBCT to minimize the subjects' exposure to radiation.

Soft tissue healing will be assessed at 2, 8 and 12 weeks with a wound-healing index (WHI) according to the following scheme: score "1" for uneventful wound healing with no gingival edema, erythema, suppuration, discomfort or graft exposure; score "2" for uneventful wound healing with slight gingival edema, erythema, or discomfort, but minimal loss of graft and no suppuration; score "3" for poor wound healing with significant gingival edema, erythema, discomfort, loss of graft or any suppuration.

Re-entry surgery will be performed at 12 weeks, and all clinical measurements will be repeated. Crestal flapless soft tissue and bone core biopsies approximately 2.7 x 10 mm in size will be removed with a 3.2 mm trephine drill from the area corresponding to the center of the previous extraction from the crest of the ridge using the occlusal template as a guide.

The cores will be placed in bottles of 10% neutral buffered formalin (NBF) for fixation, and then labeled with a 5-digit number in order to permit masked histomorphometric analysis. Analysis will be performed in the outer aspect of the bone cores, which correspond to the bone surface that will contact the dental implants at the time of placement. Zimmer TSTV implants will be placed at the same time the second re-entry procedure is done. All implants will be placed according to the manufacturer's specifications. Restorative treatment will be initiated 90 days after implant placement.

Being tested
Zimmer Puros Cancellous Allograft, Nobel Biocare Creos Cancellous Allograft

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Zimmer Puros Cancellous AllograftDevice

    Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.

  • Nobel Biocare Creos Cancellous AllograftDevice

    Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.

Study groups in NCT02444052
Study groupRoleWhat they receive
Zimmer Puros Cancellous AllograftExperimentalRight side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
Receives: Device: Zimmer Puros Cancellous Allograft
Nobel Biocare Creos Cancellous AllograftExperimentalLeft side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
Receives: Device: Nobel Biocare Creos Cancellous Allograft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bone change in millimeters from initial (baseline) to full healing (week 12)

    Measured: At week 12

  2. Cone beam computed tomography bone density changes

    Measured: At week 12

  3. Percentage of bone formation in the alveolar bone core biopsies

    Measured: At week 12

  4. Percentage of volumetric bone formation observed by comparison of Cone beam computed tomography images and the percentage of residual Puros® bone cores

    Measured: At week 12

  5. Percentage of volumetric bone formation observed by comparison of Cone beam computed tomography images and the percentage of residual creos™ allograft in the bone cores

    Measured: At week 12

Secondary outcomes (5)
  1. Facial/buccal alveolar bone thickness measured in millimeters with calipers

    After extraction of the tooth, the facial/buccal bone thickness will be measured with calipers to the nearest millimeter.

    Measured: At Baseline

  2. Length of alveolar dehiscence defects measured in millimeters with a periodontal probe

    This measurement is made after the tooth is extracted and measured with a periodontal probe to the nearest millimeter

    Measured: At Baseline

  3. Width of alveolar dehiscence defects measured in millimeters with a periodontal probe

    This measurement is made after the tooth is extracted and measured with a periodontal probe to the nearest millimeter

    Measured: At Baseline

  4. Plaque score

    A disclosing solution such is painted on all exposed tooth surfaces. After the patient has rinsed, the operator (using an explorer or a tip of a probe) examines each stained surface for soft accumulations at the dentogingival junction. When found, they are recorded by making a dash/red color in the appropriate spaces on the record form. Those surfaces, which do not have soft accumulations at the dentogingival junction, are not recorded.

    Measured: Pre-op, Baseline, Week 2, 8 and 12

  5. Subjective clinical bone density on re-entry

    Assessed during osteotomy for implant placement

    Measured: At week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2015 (estimated)
  2. Study startOct 2015
  3. Primary completionJun 2017
  4. Study completion1 Oct 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02444052
Sponsor's protocol ID
IRB20150016
Status last verified
Mar 2018
First submitted
7 May 2015
Last updated
2 Apr 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Zimmer Puros Cancellous Allograft and Nobel Biocare Creos Cancellous Allograft in people with Alveolar Bone Grafting and Allograft, run by University of Florida at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bone change in millimeters from initial (baseline) to full healing (week 12) (time frame: At week 12). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2018; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in